Stockhead – ScoPo’s (actually Wilkie’s) Powerplays: Health stocks rise as AdAlta soars 17% on trial results MediaBy Nickholas Bahr08/03/2024
Small Caps Interview – PharmAust makes strong progress in monepantel study to treat MND/ALS MediaBy Nickholas Bahr01/03/2024
BioWorld – Pivotal trial next for Pharmaust after MND/ALS phase I success MediaBy Nickholas Bahr29/02/2024
ausbiz Interview – “Exciting milestone” in the fight against motor neurone disease MediaBy Nickholas Bahr29/02/2024
Stockhead – PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy MediaBy Nickholas Bahr28/02/2024
Small Caps – PharmAust’s monepantel study shows 58% slowdown in MND progression MediaBy Nickholas Bahr28/02/2024
Proactive – PharmAust advances monepantel for motor neurone disease towards FDA approval MediaBy Nickholas Bahr23/02/2024
Small Caps – PharmAust assembles world-class scientific advisory board to propel fight against neurodegenerative diseases MediaBy Nickholas Bahr22/02/2024
Stockhead – PharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALS MediaBy Nickholas Bahr22/02/2024
